BARCELONA, Spain, May 3, 2021 /PRNewswire/ -- Esteve Pharmaceuticals (ESTEVE), an international specialty pharmaceutical company devoted to the development and commercialization of innovative products, today announced an agreement with Kowa Pharmaceuticals America, Inc. (KPA) under which ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United States. E-58425 is an investigational medicinal product under development for the management of acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate[1-9].
BARCELONA, Spain, May 3, 2021 /PRNewswire/ -- Esteve Pharmaceuticals (ESTEVE), an international specialty pharmaceutical company devoted to the development and commercialization of innovative products, today announced an agreement with Kowa Pharmaceuticals America, Inc. (KPA) under which ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United States. E-58425 is an investigational medicinal product under development for the management of acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate[1-9].
Japanese drugmaker Kowa Co. Ltd. won a patent infringement trial against Amneal and Apotex on Wednesday when a New York federal judge delivered the verdict that Kowa’s patent for the statin Livalo was valid and that the defendants were not able to show it was anticipated or obviou
Livalo® (Pitavastatin Calcium): Kowa Company, Ltd. Et Al v.Hetero Drugs Limited
Cadila Healthcare, a Rs. 9,450 crore plus pharma major and its subsidiary Zydus Pharmaceuticals (USA) Inc., have finalized an agreement with Kowa Company Ltd, Kowa Pharmaceuticals America, Inc. and Nissan Chemical Industries Ltd to settle all outstanding patent litigation related to Livalo (pitavastatin calcium) tablets.
Kowa Pharmaceuticals America, Inc. today announced the presentation of new data from the INTREPID (HIV PatieNts and TREatment with Pitavastatin versus PravastatIn for Dyslipidemia) trial, showing pitavastatin significantly lowered key arterial inflammation and immune activation markers in HIV patients on chronic antiretroviral therapy (ART) compared to pravastatin, a commonly prescribed statin for HIV-infected patients with dyslipidemia. Combined with previously reported INTREPID data demonstrating superior LDL-C reduction with pitavastatin versus pravastatin (-31% vs. -21%, respectively), results suggest pitavastatin may be an ideal statin to optimally improve lipids and inflammatory markers in HIV patients.
Chugai Pharmaceutical Co., Ltd., one of Japan’s leading research-based pharmaceutical companies, and Kowa Company, Ltd. (Kowa), a privately held multinational pharmaceutical company, announced that both companies have agreed to expand the license agreement to include US and EU for Chugai’s original selective SGLT2 inhibitor, currently marketed by Kowa under the brand name “Deberza tablets 20mg” (generic name: tofogliflozin hydrate) with the indication of type 2 diabetes in Japan.